These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 35708342)

  • 1. The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma-based severity levels: Insights from a large US commercial and managed Medicaid population.
    Pollack M; Gandhi H; Tkacz J; Lanz M; Lugogo N; Gilbert I
    J Manag Care Spec Pharm; 2022 Aug; 28(8):881-891. PubMed ID: 35708342
    [No Abstract]   [Full Text] [Related]  

  • 2. Incremental cost burden among patients with severe uncontrolled asthma in the United States.
    Burnette A; Wang Y; Rane PB; Chung Y; Princic N; Park J; Llanos JP; Lindsley AW; Ambrose CS
    J Manag Care Spec Pharm; 2023 Jul; 29(7):825-834. PubMed ID: 37404066
    [No Abstract]   [Full Text] [Related]  

  • 3. Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America.
    Quint JK; Arnetorp S; Kocks JWH; Kupczyk M; Nuevo J; Plaza V; Cabrera C; Raherison-Semjen C; Walker B; Penz E; Gilbert I; Lugogo NL; van der Valk RJP;
    J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2297-2309.e10. PubMed ID: 35364341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-world patterns and implications of short-acting β
    Lugogo N; Gilbert I; Tkacz J; Gandhi H; Goshi N; Lanz MJ
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):681-689.e1. PubMed ID: 33515710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study.
    Evans KA; Pollack M; Portillo E; Strange C; Touchette DR; Staresinic A; Patel S; Tkacz J; Feigler N
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1366-1377. PubMed ID: 36427341
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States.
    Wu SS; Perry A; Tkacz J; Bryant G
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1010-1020. PubMed ID: 37610115
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis.
    Beasley R; Harrison T; Peterson S; Gustafson P; Hamblin A; Bengtsson T; Fagerås M
    JAMA Netw Open; 2022 Mar; 5(3):e220615. PubMed ID: 35230437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of Rescue and Maintenance Medication Claims Surrounding an Asthma Exacerbation in Patients Treated as Intermittent or Mild Persistent Asthma.
    Lanz MJ; Pollack M; Gilbert IA; Gandhi HN; Tkacz JP; Lugogo NL
    J Asthma Allergy; 2024; 17():871-877. PubMed ID: 39296429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
    Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
    J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
    [No Abstract]   [Full Text] [Related]  

  • 12. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.
    Chastek B; Korrer S; Nagar SP; Albers F; Yancey S; Ortega H; Forshag M; Dalal AA
    J Manag Care Spec Pharm; 2016 Jul; 22(7):848-61. PubMed ID: 27348285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
    Strand V; Tundia N; Song Y; Macaulay D; Fuldeore M
    J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
    Xing S; Batt K; Kuharic M; Bullano M; Caicedo J; Chakladar S; Markan R; Farahbakhshian S
    J Manag Care Spec Pharm; 2023 Jun; 29(6):626-634. PubMed ID: 37276033
    [No Abstract]   [Full Text] [Related]  

  • 15. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
    Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
    [No Abstract]   [Full Text] [Related]  

  • 16. Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio.
    Luskin AT; Antonova EN; Broder MS; Chang E; Raimundo K; Solari PG
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1117-1124. PubMed ID: 29083971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of rescue and maintenance therapy claims surrounding a clinical encounter for an asthma exacerbation.
    Lanz MJ; Gilbert IA; Gandhi HN; Pollack M; Tkacz JP; Lugogo NL
    Ann Allergy Asthma Immunol; 2023 Oct; 131(4):458-465.e1. PubMed ID: 37343824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
    Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
    Sanchez L; Chari A; Cheng M; Cherepanov D; DerSarkissian M; Huang F; Stull DM; Dabora J; Young M; Noga SJ; Pi S; Zhang M; Banatwala A; Duh MS; Ailawadhi S
    J Manag Care Spec Pharm; 2023 Nov; 29(11):1205-1218. PubMed ID: 37776124
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.